Study 31 / A5349
2021
Four-Month Rifapentine-Based Regimen for Drug-Susceptible TB
In 2,516 patients with drug-susceptible pulmonary tuberculosis, a 4-month regimen of high-dose rifapentine plus moxifloxacin was non-inferior to the standard 6-month regimen for TB-free survival.
Result
- Absolute difference
- 1 points
The absolute difference is derived from the event rates.
Also reported: Non-inferior.
- Subtopic
- Drug-susceptible TB
- Design
- Open-label non-inferiority RCT
- Relevance
- Important: one of several pillars.
- Source
- Dorman SE, et al. N Engl J Med. 2021;384(18):1705-1718.doi 10.1056/NEJMoa2033400
Discussion & critique
First WHO- and CDC-endorsed 4-month regimen for drug-susceptible pulmonary TB in patients ≥12 years, a major step from 6 to 4 months.